Loading company…
PrimeGene develops drugs for immune-inflammatory diseases across dermatology, ophthalmology, rhinology and respiratory care.
Founded in 2016, PrimeGene researches and develops drugs for immune-inflammatory diseases, with programs in dermatology, ophthalmology, rhinology and respiratory conditions. Its products include PG-019 and PG-033, and target conditions such as atopic dermatitis and glaucoma. The company is based in Beijing, China, and was listed on the New Third Board in 2022. In January 2025, it raised more than CNY 300 million in Series B funding from Zhengqi Financial Holdings Corporation, Tech-Intelligence Capital, Beijing Capital Technology Development Group, Shunlong Private Equity Bond Investment, E-Town International Industrial Investment and other investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in